論文

国際誌
2020年12月16日

Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.

Japanese journal of clinical oncology
  • Toshio Kubo
  • Hiromi Watanabe
  • Kiichiro Ninomiya
  • Kenichiro Kudo
  • Daisuke Minami
  • Etsuko Murakami
  • Nobuaki Ochi
  • Takashi Ninomiya
  • Daijiro Harada
  • Masayuki Yasugi
  • Eiki Ichihara
  • Kadoaki Ohashi
  • Kammei Rai
  • Keiichi Fujiwara
  • Katsuyuki Hotta
  • Masahiro Tabata
  • Yoshinobu Maeda
  • Katsuyuki Kiura
  • 全て表示

50
12
開始ページ
1447
終了ページ
1453
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/jjco/hyaa152
出版者・発行元
OXFORD UNIV PRESS

OBJECTIVES: Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged ≥65 years, but the effects in patients aged ≥75 years are controversial. We performed multicenter, collaborative and retrospective analyses of immune checkpoint inhibitor efficacy and safety in non-small cell lung cancer patients aged ≥75 years. METHODS: We retrospectively studied 434 advanced non-small cell lung cancer patients who received immune checkpoint inhibitors from December 2015 to December 2017, and retrospectively applied the Geriatric (G) 8 screening tool with medical records. RESULTS: Of the 434 patients who received immune checkpoint inhibitors, 100 were aged ≥75 years. Five patients with performance status 3 were omitted from the final analysis. Immune checkpoint inhibitors were given as a first-line treatment to 20 patients. The objective response rates, median progression-free survival rates and median survival times were 35.0%, 6.1 months and 10.7 months for first-line treatment, and 20.0%, 2.9 months and 14.7 months for second- or later-line treatments, respectively. The median modified G8 score was 11.0. The median survival time was longer in the high modified G8 (≥12.0) group than in the low modified G8 (≤11.0) group (18.7 vs. 8.7 months; P = 0.02). Likewise, the median survival time was 15.5 months (performance status 0-1) vs. 3.2 months (performance status 2) (P < 0.01). The grade ≥ 2 immune-related adverse events incidence was 36.8%. CONCLUSIONS: In this study, immune checkpoint inhibitors were effective and tolerable for patients aged ≥75 years. The modified G8 screening tool and performance status were associated with the outcome of older non-small cell lung cancer patients treated with immune checkpoint inhibitors.

リンク情報
DOI
https://doi.org/10.1093/jjco/hyaa152
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32869100
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000605982500013&DestApp=WOS_CPL
ID情報
  • DOI : 10.1093/jjco/hyaa152
  • ISSN : 0368-2811
  • eISSN : 1465-3621
  • PubMed ID : 32869100
  • Web of Science ID : WOS:000605982500013

エクスポート
BibTeX RIS